As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > REGULATORY
REGULATORY
- Label Revision Ordered for Acetaminophen to Add Drug-Induced Hypersensitivity Syndrome as ADR
January 19, 2023
- Label Expansions for Nubeqa, Rinvoq, Imbruvica on PAFSC Agenda for Feb. 1
January 19, 2023
- Japan Likely to Downgrade Severity Classification for COVID-19
January 19, 2023
- Chuikyo’s Drug Pricing Debate Slated to Begin in May after Expert Panel Proposal
January 19, 2023
- Emgality, Revestive, Veklury Brace for Price Cuts under CEA Scheme
January 19, 2023
- Former Minister Nemoto to Initiate Debates on Pharma Policies by Young Lawmakers
January 19, 2023
- 5 Wholesalers to Be Slapped with 600 Million Yen Surcharges over Kyushu Bid-Rigging Case
January 18, 2023
- METI Aims at “1 or 2” Returns of Several 10s of Billions of Yen a Year from Biotech Ecosystem Program: Official
January 18, 2023
- HES Preparations Now Contraindicated in Patients with Severe Sepsis: Label Revisions
January 18, 2023
- Ex-Minister Tamura Hightlights Need for Rewarding Innovation towards FY2024 Drug Reform
January 17, 2023
- MHLW Panel to Discuss Semaglutide for Obesity, Precedex, Entyvio SC on Jan. 27
January 17, 2023
- Experts Call for Deregulations for Orphan Support, English Dossiers to Foster Biotech Ecosystem
January 16, 2023
- MHLW Panel OKs 64 More Health Damage Claims for COVID-19 Vaccines
January 16, 2023
- MHLW Panel Urges Better Application of Emergency Approval
January 16, 2023
- MHLW Likely to Give Up Submitting Bill to Lift Bans on Cannabis-Derived Drugs
January 13, 2023
- MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
January 13, 2023
- Japan Panel Recognizes 5 More Deaths Possibly Tied to COVID Vaccines
January 13, 2023
- PMP, Off-Patent Drug Rules to Be Major Topics for 2024 Reform: MHLW Pharma Management Director
January 12, 2023
- Japan to Boost Review of Health Damage Claims for COVID-19 Vaccines
January 12, 2023
- 4 Cases of New COVID Variant XBB.1.5 Confirmed in Japan: Govt
January 12, 2023
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…